Mechanisms underlying the blood pressure lowering effects of dapagliflozin, exenatide, and their combination in people with type 2 diabetes: a secondary analysis of a randomized trial

被引：0
|
作者：
Charlotte C. van Ruiten
Mark M. Smits
Megan D. Kok
Erik H. Serné
Daniël H. van Raalte
Mark H. H. Kramer
Max Nieuwdorp
Richard G. IJzerman
机构：
[1] Diabetes Center,Department of Internal Medicine
[2] Amsterdam University Medical Center,Department of Vascular Medicine
[3] Location VU University Medical Center,Department of Vascular Medicine
[4] Amsterdam University Medical Center,Department of Internal Medicine
[5] Location VU University Medical Center,undefined
[6] Amsterdam University Medical Center,undefined
[7] Location AMC,undefined
[8] Amsterdam Diabetes Center,undefined
[9] Amsterdam University Medical Centers (Amsterdam UMC),undefined
[10] Location VU University Medical Center (VUMC),undefined
来源：
Cardiovascular Diabetology | / 21卷
关键词：
SGLT2 inhibitor; Dapagliflozin; GLP-1 receptor agonist; Exenatide; Type 2 diabetes; Blood pressure; Autonomic balance; Hemodynamics;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [1] Mechanisms underlying the blood pressure lowering effects of dapagliflozin, exenatide, and their combination in people with type 2 diabetes: a secondary analysis of a randomized trial
    van Ruiten, Charlotte C.
    Smits, Mark M.
    Kok, Megan D.
    Serne, Erik H.
    van Raalte, Daniel H.
    Kramer, Mark H. H.
    Nieuwdorp, Max
    IJzerman, Richard G.
    CARDIOVASCULAR DIABETOLOGY, 2022, 21 (01)
  • [2] Mechanisms underlying the blood pressure-lowering effects of empagliflozin, losartan and their combination in people with type 2 diabetes: A secondary analysis of a randomized crossover trial
    Scholtes, Rosalie A.
    Mosterd, Charlotte M.
    Hesp, Anne C.
    Smits, Mark M.
    Heerspink, Hiddo J. L.
    van Raalte, Daniel H.
    DIABETES OBESITY & METABOLISM, 2023, 25 (01): : 198 - 207
  • [3] Albuminuria lowering effect of dapagliflozin, exenatide and their combination in patients with type 2 diabetes: a randomised cross-over clinical trial
    van der Aart-van der Beek, A. B.
    Apperloo, E.
    Jongs, N.
    Rouw, D. B.
    Sjostrom, D.
    van Raalte, D. H.
    Hoogenberg, K.
    Heerspink, H. J. L.
    DIABETOLOGIA, 2022, 65 (SUPPL 1) : S387 - S387
  • [4] Albuminuria-lowering effect of dapagliflozin, exenatide, and their combination in patients with type 2 diabetes: A randomized cross-over clinical study
    van der Aart-van Der Beek, Annemarie B.
    Apperloo, Ellen
    Jongs, Niels
    Rouw, Dennis B.
    Sjostrom, C. David
    Friedli, Iris
    Johansson, Lars
    van Raalte, Daniel H.
    Hoogenberg, Klaas
    Heerspink, Hiddo J. L.
    DIABETES OBESITY & METABOLISM, 2023, 25 (06): : 1758 - 1768
  • [5] Effect of exenatide twice daily and dapagliflozin, alone and in combination, on markers of kidney function in obese patients with type 2 diabetes: A prespecified secondary analysis of a randomized controlled clinical trial
    van Ruiten, Charlotte C.
    Van der Aart-van der Beek, Annemarie B.
    IJzerman, Richard G.
    Nieuwdorp, Max
    Hoogenberg, K.
    van Raalte, Daniel H.
    Heerspink, Hiddo J. L.
    DIABETES OBESITY & METABOLISM, 2021, 23 (08): : 1851 - 1858
  • [6] Effects of Exenatide on Systolic Blood Pressure in Subjects With Type 2 Diabetes
    Okerson, Ted
    Yan, Ping
    Stonehouse, Anthony
    Brodows, Robert
    AMERICAN JOURNAL OF HYPERTENSION, 2010, 23 (03) : 334 - 339
  • [7] Liver-related effects of exenatide and dapagliflozin in type 2 diabetes
    Kahl, Sabine
    DIABETOLOGE, 2020, 16 (05): : 533 - 534
  • [8] Combination blood pressure lowering therapy in patients with type 2 diabetes: messages from the ADVANCE trial
    Wang, Nelson
    Chalmers, John
    Harris, Katie
    Poulter, Neil
    Mancia, Giuseppe
    Harrap, Stephen
    Hamet, Pavel
    Grobbee, Diederick E.
    Marre, Michel
    Woodward, Mark
    JOURNAL OF HYPERTENSION, 2024, 42 (12) : 2055 - 2064
  • [9] Glycemic and Weight Lowering Effects of Exenatide Once Weekly Are Associated with Blood Pressure Changes in Patients with Type 2 Diabetes
    Paul, Sanjoy
    Best, Jennie H.
    Klein, Kerenaftali
    Han, Jenny
    Maggs, David
    DIABETES, 2011, 60 : A296 - A296
  • [10] Blood Pressure Lowering and Outcomes in type 2 Diabetes: Implications of the Blood Pressure-Lowering Arm of the Advance Trial
    MacIsaac, Richard J.
    Barit, David
    Jerums, George
    CURRENT HYPERTENSION REVIEWS, 2009, 5 (03) : 168 - 180
12345